miR-196b Is Epigenetically Silenced during the Premalignant Stage of Lung Carcinogenesis.
miRNA silencing by promoter hypermethylation may represent a mechanism by which lung cancer develops and progresses, but the miRNAs involved during malignant transformation are unknown. We previously established a model of premalignant lung cancer wherein we treated human bronchial epithelial cells (HBEC) with low doses of tobacco carcinogens. Here, we demonstrate that next-generation sequencing of carcinogen-transformed HBECs treated with the demethylating agent 5-aza-2'deoxycytidine revealed miR-196b and miR-34c-5p to be epigenetic targets. Bisulfite sequencing confirmed dense promoter hypermethylation indicative of silencing in multiple malignant cell lines and primary tumors. Chromatin immunoprecipitation studies further demonstrated an enrichment in repressive histone marks on the miR-196b promoter during HBEC transformation. Restoration of miR-196b expression by transfecting transformed HBECs with specific mimics led to cell-cycle arrest mediated in part through transcriptional regulation of the FOS oncogene, and miR-196b reexpression also significantly reduced the growth of tumor xenografts. Luciferase assays demonstrated that forced expression of miR-196b inhibited the FOS promoter and AP-1 reporter activity. Finally, a case-control study revealed that methylation of miR-196b in sputum was strongly associated with lung cancer (OR = 4.7, P < 0.001). Collectively, these studies highlight miR-196b as a tumor suppressor whose silencing early in lung carcinogenesis may provide a selective growth advantage to premalignant cells. Targeted delivery of miR-196b could therefore serve as a preventive or therapeutic strategy for the management of lung cancer. Cancer Res; 76(16); 4741-51. ©2016 AACR.
Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico. ctellez@LRRI.org sbelinsk@LRRI.org.
Carmen S
CS
Tellez
Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Daniel E
DE
Juri
Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Kieu
K
Do
Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Maria A
MA
Picchi
Department of Medicine, Boston University, Boston, Massachusetts.
Teresa
T
Wang
Department of Medicine, Boston University, Boston, Massachusetts.
Gang
G
Liu
Department of Medicine, Boston University, Boston, Massachusetts.
Avrum
A
Spira
Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico. ctellez@LRRI.org sbelinsk@LRRI.org.
Steven A
SA
Belinsky
D000818:Animals; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D047369:Chromatin Immunoprecipitation; D019175:DNA Methylation; D044127:Epigenesis, Genetic / Q000235:genetics*; D005260:Female; D064593:Heterografts; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D016133:Polymerase Chain Reaction
C542543:MIRN196 microRNA, human; D035683:MicroRNAs